Human clinical trials scheduled
Scientists may have overcome a major roadblock in the development of Alzheimer’s therapies by creating a new technology to observe ? in the back of the eye ? progression of the disease before the onset of symptoms. Clinical trials are to start in July to test the technology in humans according to a paper recently published in Investigative Ophthalmology & Visual Science (IOVS).
The paper, titled Early detection of amyloidopathy in Alzheimer’s mice by hyperspectral endoscopy, builds upon previous work in cells by detecting changes in the retina of mice predisposed to develop Alzheimer’s.
Early detection of Alzheimer’s is critical for two reasons. “First, effective treatments need to be administered well before patients show actual neurological signs,” said author Robert Vince, PhD, of the Center for Drug Design at the University of Minnesota (UMN). “Second, since there are no available early detection techniques, drugs currently cannot be tested to determine if they are effective against early Alzheimer’s disease. An early diagnostic tool like ours could help the development of drugs as well.”
Looking through the eye to see the brain is a key advantage of the new technology. “The retina of the eye is not just ‘connected’ to the brain — it is part of the central nervous system,” said author Swati More, PhD, also of the Center for Drug Design at UMN. While the brain and retina undergo similar changes due to Alzheimer’s disease, “unlike the brain, the retina is easily accessible to us, making changes in the retina easier to observe.”
“We saw changes in the retinas of Alzheimer’s mice before the typical age at which neurological signs are observed,” said More. “The results are close to our best-case scenario for outcomes of this project.”
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Gamechanger: Blood test can predict if patients will develop Alzheimer's disease in the futureon December 1, 2020 at 9:14 pm
Scientists said Monday they had developed a way of predicting if patients will develop Alzheimer's disease by analysing their blood, in what experts hailed as a potential "gamechanger" in the fight ...
- New tests identify early changes in Alzheimer’s disease before symptoms appearon December 1, 2020 at 8:11 pm
Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop. The scientists developed new tools to detect ...
- First Alzheimer's blood test now on the market, without FDA approvalon December 1, 2020 at 1:00 pm
More than 5 million people in the United States and millions more around the world have Alzheimer's, the most common form of dementia.
- New blood test to help diagnose Alzheimer's comes with a caveaton December 1, 2020 at 10:27 am
The new test is not approved by the FDA and is not supported by the Alzheimer's Association. But advocates are encouraged by the research.
- First Alzheimer’s Blood Test Now On Sale Only With Doctor’s Orderon December 1, 2020 at 10:21 am
AP reports that the blood test has not been approved by the FDA and is not covered by insurance or Medicare. Its maker, C2N Diagnostics of St. Louis, charges $1,250 and offers discounts based on ...
- AI uses retinal scans to spot Alzheimer’son December 1, 2020 at 10:01 am
A new AI model that examines retina images for changes that point to Alzheimer's disease may one day help diagnose the disease.
- Could Dirty Air Help Speed Alzheimer's?on December 1, 2020 at 8:47 am
Older adults exposed to air pollution might have a heightened risk of abnormal "plaque" accumulation in the brain, a new study suggests. Plaques refer to clumps of protein called beta-amyloid that ...
- First blood test to help diagnose Alzheimer’s goes on saleon December 1, 2020 at 8:37 am
AP A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also ...
- Blood test for Alzheimer's goes on sale without FDA approvalon December 1, 2020 at 7:44 am
St. Louis-based C2N Diagnostics has released a blood test that it says can detect Alzheimer's disease. The test is not yet FDA approved, and is not covered by insurance, costing up to $1,250.
- Cleveland-Area Resident Elected to Lead Alzheimer's Association Board of Directorson December 1, 2020 at 7:00 am
The Alzheimer's Association has elected Brian J. Richardson from Avon Lake, Ohio, as Chair of its Board of Directors. Richardson, who was first elected to the Association's Board of Directors in 2013, ...
via Bing News